Pancreatic Cancer Research

ResearcherLoyola University Medical CenterActive in the last 2 years

Robert Marsh

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1871-096X; OpenAlex author ID A5013408333. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
39
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: 2 papers · 2016: 2 papers · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 11

  1. Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 St… Co-author DOI 10.1200/jco-25-00746↗
  2. Pathologic Response to Primary Systemic Therapy With FOLFIRINOX in Patients With Resectable Pancreatic Cancer. Last author DOI 10.1097/coc.0000000000000601↗
  3. Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study. Co-author DOI 10.1002/jso.24872↗
  4. Does adjuvant radiation provide any survival benefit after an R1 resections for pancreatic cancer? Co-author DOI 10.1016/j.surg.2017.09.022↗
  5. Neoadjuvant external beam radiation is associated with No benefit in overall survival for early stage pancreatic cancer. Co-author DOI 10.1016/j.amjsurg.2016.11.039↗
  6. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Tri… Co-author DOI 10.1001/jamasurg.2016.1137↗
  7. External radiation is associated with limited improvement in overall survival in resected margin-negative stage IIB pancreatic adenocarcinoma. Co-author DOI 10.1016/j.surg.2016.07.033↗
  8. Pancreatic cancer and FOLFIRINOX: a new era and new questions. Co-author DOI 10.1002/cam4.433↗
  9. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. Co-author DOI 10.1200/jco.2015.62.8719↗
  10. CA 19-9 nonproduction is associated with poor survival after resection of pancreatic adenocarcinoma. Co-author DOI 10.1097/coc.0b013e318280d5f0↗
  11. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. First author DOI 10.1245/s10434-013-2886-9↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marina Talamonti · 7 shared papers, 2014–2018 · strength 0.44
  2. Marshall S. Baker · 5 shared papers, 2014–2018 · strength 0.32
  3. Richard A. Prinz · 4 shared papers, 2014–2018 · strength 0.25
  4. Kevin King Roggin · 3 shared papers, 2017–2018 · strength 0.21
  5. Hedy Lee Kindler · 4 shared papers, 2013–2018 · strength 0.18
  6. David J. Bentrem · 3 shared papers, 2014–2018 · strength 0.18
  7. Ariel Polish · 1 shared paper, 2019 · strength 0.16
  8. Matthew H. G. Katz · 3 shared papers, 2013–2016 · strength 0.15
  9. Joseph M. Herman · 3 shared papers, 2013–2016 · strength 0.15
  10. Waseem Lutfi · 2 shared papers, 2016–2017 · strength 0.13
  11. Olga Kantor · 2 shared papers, 2016–2017 · strength 0.13
  12. Daniel V.T. Catenacci · 2 shared papers, 2015–2018 · strength 0.11
  13. Mitchell C. Posner · 2 shared papers, 2013–2018 · strength 0.10
  14. Syed Ameen Ahmad · 2 shared papers, 2013–2016 · strength 0.08
  15. Alan Paul Venook · 2 shared papers, 2013–2016 · strength 0.08
  16. Andrew M. Lowy · 2 shared papers, 2013–2016 · strength 0.08
  17. Philip A. Philip · 2 shared papers, 2013–2016 · strength 0.08
  18. Jeffrey B. Matthews · 1 shared paper, 2018 · strength 0.07
  19. Blasé N. Polite · 1 shared paper, 2018 · strength 0.07
  20. Nicholas R. Suss · 1 shared paper, 2018 · strength 0.07
  21. Amanda V. Hayman · 1 shared paper, 2014 · strength 0.05
  22. William Charles Conway · 1 shared paper, 2016 · strength 0.04
  23. John Parker Hoffman · 1 shared paper, 2016 · strength 0.04
  24. Eric Andrew Collisson · 1 shared paper, 2016 · strength 0.04
  25. Noelle K. LoConte · 1 shared paper, 2016 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.